Lead Program

Plixorafenib Program

Our lead program focuses on plixorafenib, an investigational, next-generation BRAF inhibitor identified by our platform for its ability to inhibit a wide range of BRAF gene alterations in cancer cells beyond those targeted by earlier-generation BRAF inhibitors.

Building our pipeline

We focus primarily on compounds that have passed phase 1 trials and are proven to be safe, for which the main challenge is pinpointing which patient populations they will benefit most. We also consider pre-IND compounds where the biology is well understood and clinical trials are within sight.

We continue to consider licensing opportunities. To discuss a potential collaboration, please contact our business development team at: oib.e1721791924rof@r1721791924entra1721791924p1721791924.